Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 78 entries
Sorted by: Best Match Show Resources per page
Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.

The American journal of tropical medicine and hygiene

Chechi F, Corsi P, Bartolozzi D, Gaiera G, Bartoloni A, Zammarchi L.
PMID: 34781255
Am J Trop Med Hyg. 2021 Nov 15; doi: 10.4269/ajtmh.21-0600. Epub 2021 Nov 15.

The management of visceral leishmaniasis (VL) in HIV-infected patients is complex because of high mortality rates, toxic drug-related side effects, and a high risk of treatment failure and relapse. We report a case of active chronic VL in an...

Cite
Chechi F, Corsi P, Bartolozzi D, et al. Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient. Am J Trop Med Hyg. 2021;doi: 10.4269/ajtmh.21-0600.
Chechi, F., Corsi, P., Bartolozzi, D., Gaiera, G., Bartoloni, A., & Zammarchi, L. (2021). Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient. The American journal of tropical medicine and hygiene, . https://doi.org/10.4269/ajtmh.21-0600
Chechi, Flavia, et al. "Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient." The American journal of tropical medicine and hygiene vol. (2021). doi: https://doi.org/10.4269/ajtmh.21-0600
Chechi F, Corsi P, Bartolozzi D, Gaiera G, Bartoloni A, Zammarchi L. Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient. Am J Trop Med Hyg. 2021 Nov 15; doi: 10.4269/ajtmh.21-0600. Epub 2021 Nov 15. PMID: 34781255.
Copy Download .nbib Format: NLM
Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro.

Drug design, development and therapy

Wu Y, Zhang Z, Kou Z.
PMID: 34234416
Drug Des Devel Ther. 2021 Jul 01;15:2857-2868. doi: 10.2147/DDDT.S311187. eCollection 2021.

PURPOSE: Pentamidine is an anti-protozoal cationic aromatic diamidine drug and has been reported to exhibit anticancer properties. We aimed to identify the effect of pentamidine on proliferation and migration of human ovarian cancer (OC) cell lines and the related...

Cite
Wu Y, Zhang Z, Kou Z. Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro. Drug Des Devel Ther. 2021;15:2857-2868doi: 10.2147/DDDT.S311187.
Wu, Y., Zhang, Z., & Kou, Z. (2021). Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro. Drug design, development and therapy, 152857-2868. https://doi.org/10.2147/DDDT.S311187
Wu, Yi, et al. "Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro." Drug design, development and therapy vol. 15 (2021): 2857-2868. doi: https://doi.org/10.2147/DDDT.S311187
Wu Y, Zhang Z, Kou Z. Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro. Drug Des Devel Ther. 2021 Jul 01;15:2857-2868. doi: 10.2147/DDDT.S311187. eCollection 2021. PMID: 34234416; PMCID: PMC8257069.
Copy Download .nbib Format: NLM
Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry.

Rheumatology (Oxford, England)

Sonomoto K, Tanaka H, Nguyen TM, Yoshinari H, Nakano K, Nakayamada S, Tanaka Y.
PMID: 34382090
Rheumatology (Oxford). 2021 Aug 11; doi: 10.1093/rheumatology/keab647. Epub 2021 Aug 11.

OBJECTIVES: The use of biologics and targeted-synthetic (b/ts) DMARDs in the treatment of rheumatoid arthritis (RA) is increasing. Therefore, prevention of b/tsDMARDs-induced infection is important. Here we describe a prophylaxis protocol to prevent pneumocystis pneumonia (PCP) in RA patients...

Cite
Sonomoto K, Tanaka H, Nguyen TM, et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab647.
Sonomoto, K., Tanaka, H., Nguyen, T. M., Yoshinari, H., Nakano, K., Nakayamada, S., & Tanaka, Y. (2021). Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab647
Sonomoto, Koshiro, et al. "Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab647
Sonomoto K, Tanaka H, Nguyen TM, Yoshinari H, Nakano K, Nakayamada S, Tanaka Y. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: Insights from 3,787 cases in FIRST registry. Rheumatology (Oxford). 2021 Aug 11; doi: 10.1093/rheumatology/keab647. Epub 2021 Aug 11. PMID: 34382090.
Copy Download .nbib Format: NLM
Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

ACS infectious diseases

Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI.
PMID: 34766746
ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12.

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here...

Cite
Wesseling CMJ, Slingerland CJ, Veraar S, et al. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021;7(12):3314-3335doi: 10.1021/acsinfecdis.1c00466.
Wesseling, C. M. J., Slingerland, C. J., Veraar, S., Lok, S., & Martin, N. I. (2021). Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS infectious diseases, 7(12), 3314-3335. https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling, Charlotte M J, et al. "Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens." ACS infectious diseases vol. 7,12 (2021): 3314-3335. doi: https://doi.org/10.1021/acsinfecdis.1c00466
Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12. PMID: 34766746; PMCID: PMC8669655.
Copy Download .nbib Format: NLM
Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery.

Pharmaceutics

Rinaldi F, Hanieh PN, Chan LKN, Angeloni L, Passeri D, Rossi M, Wang JT, Imbriano A, Carafa M, Marianecci C.
PMID: 29565809
Pharmaceutics. 2018 Mar 22;10(2). doi: 10.3390/pharmaceutics10020038.

The aim of this in vitro study is to prepare and characterize drug free and pentamidine loaded chitosan glutamate coated niosomes for intranasal drug delivery to reach the brain through intranasal delivery. Mucoadhesive properties and stability testing in various...

Cite
Rinaldi F, Hanieh PN, Chan LKN, et al. Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery. Pharmaceutics. 2018;10(2)doi: 10.3390/pharmaceutics10020038.
Rinaldi, F., Hanieh, P. N., Chan, L. K. N., Angeloni, L., Passeri, D., Rossi, M., Wang, J. T., Imbriano, A., Carafa, M., & Marianecci, C. (2018). Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery. Pharmaceutics, 10(2), . https://doi.org/10.3390/pharmaceutics10020038
Rinaldi, Federica, et al. "Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery." Pharmaceutics vol. 10,2 (2018). doi: https://doi.org/10.3390/pharmaceutics10020038
Rinaldi F, Hanieh PN, Chan LKN, Angeloni L, Passeri D, Rossi M, Wang JT, Imbriano A, Carafa M, Marianecci C. Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery. Pharmaceutics. 2018 Mar 22;10(2). doi: 10.3390/pharmaceutics10020038. PMID: 29565809; PMCID: PMC6027090.
Copy Download .nbib Format: NLM
Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Brown KS, Reed MD, Dalal J, Makii MD.
PMID: 32071585
J Pediatr Pharmacol Ther. 2020;25(2):111-116. doi: 10.5863/1551-6776-25.2.111.

OBJECTIVES: Pentamidine is an antifungal that is used alternatively to sulfamethoxazole-trimethoprim for the prophylaxis and treatment of Pneumocystis jirovecii pneumonia (PJP). The primary objective of this study was to assess the tolerability of aerosolized versus intravenous pentamidine for PJP...

Cite
Brown KS, Reed MD, Dalal J, et al. Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients. J Pediatr Pharmacol Ther. 2020;25(2):111-116doi: 10.5863/1551-6776-25.2.111.
Brown, K. S., Reed, M. D., Dalal, J., & Makii, M. D. (2020). Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 25(2), 111-116. https://doi.org/10.5863/1551-6776-25.2.111
Brown, Kelsey S, et al. "Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 25,2 (2020): 111-116. doi: https://doi.org/10.5863/1551-6776-25.2.111
Brown KS, Reed MD, Dalal J, Makii MD. Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients. J Pediatr Pharmacol Ther. 2020;25(2):111-116. doi: 10.5863/1551-6776-25.2.111. PMID: 32071585; PMCID: PMC7025749.
Copy Download .nbib Format: NLM
[No title available]

Neuro-oncology practice

Skorupan N, Ranjan S, Mehta S, Yankulina O, Nenortas N, Grossman S, Ye X, Holdhoff M.
PMID: 31386039
Neurooncol Pract. 2019 Jul;6(4):321-326. doi: 10.1093/nop/npy049. Epub 2018 Nov 29.

METHODS: An online survey of 14 multiple choice questions was sent to 207 neuro-oncologists and medical oncologists treating brain cancers at all National Cancer Institute-designated cancer centers in the United States. Recipients were identified via a search of the...

Cite
Skorupan N, Ranjan S, Mehta S, et al. . Neurooncol Pract. 2018;6(4):321-326doi: 10.1093/nop/npy049.
Skorupan, N., Ranjan, S., Mehta, S., Yankulina, O., Nenortas, N., Grossman, S., Ye, X., & Holdhoff, M. (2019). . Neuro-oncology practice, 6(4), 321-326. https://doi.org/10.1093/nop/npy049
Skorupan, Nebojša, et al. "." Neuro-oncology practice vol. 6,4 (2019): 321-326. doi: https://doi.org/10.1093/nop/npy049
Skorupan N, Ranjan S, Mehta S, Yankulina O, Nenortas N, Grossman S, Ye X, Holdhoff M. . Neurooncol Pract. 2019 Jul;6(4):321-326. doi: 10.1093/nop/npy049. Epub 2018 Nov 29. PMID: 31386039; PMCID: PMC6660813.
Copy Download .nbib Format: NLM
Treatment and prophylaxis for Pneumocystis carinii pneumonia.

Parasitology today (Personal ed.)

Hughes WT.
PMID: 15462879
Parasitol Today. 1987 Nov;3(11):332-5. doi: 10.1016/0169-4758(87)90116-5.

Without treatment, Pneumocystis carinii pneumonitis is almost always fatal in the immunocompromised host. Here, Walter Hughes discusses proven and potential treatments, and methods of chemoprophylaxis in high-risk patients. Two drugs, pentamidine isethionate and trimethoprimsulfamethoxazole, are equally effective therapeutically -...

Cite
Hughes WT. Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today. 1987;3(11):332-5doi: 10.1016/0169-4758(87)90116-5.
Hughes, W. T. (1987). Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitology today (Personal ed.), 3(11), 332-5. https://doi.org/10.1016/0169-4758(87)90116-5
Hughes, W T. "Treatment and prophylaxis for Pneumocystis carinii pneumonia." Parasitology today (Personal ed.) vol. 3,11 (1987): 332-5. doi: https://doi.org/10.1016/0169-4758(87)90116-5
Hughes WT. Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today. 1987 Nov;3(11):332-5. doi: 10.1016/0169-4758(87)90116-5. PMID: 15462879.
Copy Download .nbib Format: NLM
Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin.

PLoS neglected tropical diseases

Vodnala SK, Ferella M, Lundén-Miguel H, Betha E, van Reet N, Amin DN, Oberg B, Andersson B, Kristensson K, Wigzell H, Rottenberg ME.
PMID: 19652702
PLoS Negl Trop Dis. 2009 Aug 04;3(8):e495. doi: 10.1371/journal.pntd.0000495.

BACKGROUND: There is an urgent need to substitute the highly toxic compounds still in use for treatment of the encephalitic stage of human African trypanosomiasis (HAT). We here assessed the treatment with the doublet cordycepin and the deaminase inhibitor...

Cite
Vodnala SK, Ferella M, Lundén-Miguel H, et al. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009;3(8):e495doi: 10.1371/journal.pntd.0000495.
Vodnala, S. K., Ferella, M., Lundén-Miguel, H., Betha, E., van Reet, N., Amin, D. N., Oberg, B., Andersson, B., Kristensson, K., Wigzell, H., & Rottenberg, M. E. (2009). Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS neglected tropical diseases, 3(8), e495. https://doi.org/10.1371/journal.pntd.0000495
Vodnala, Suman K, et al. "Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin." PLoS neglected tropical diseases vol. 3,8 (2009): e495. doi: https://doi.org/10.1371/journal.pntd.0000495
Vodnala SK, Ferella M, Lundén-Miguel H, Betha E, van Reet N, Amin DN, Oberg B, Andersson B, Kristensson K, Wigzell H, Rottenberg ME. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009 Aug 04;3(8):e495. doi: 10.1371/journal.pntd.0000495. PMID: 19652702; PMCID: PMC2713411.
Copy Download .nbib Format: NLM
Drug resistance in Leishmania: similarities and differences to other organisms.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Papadopoulou B, Kündig C, Singh A, Ouellette M.
PMID: 16904409
Drug Resist Updat. 1998;1(4):266-78. doi: 10.1016/s1368-7646(98)80007-1.

The main line of defense available against parasitic protozoa is chemotherapy. Drug resistance has emerged however, as a primary obstacle to the successful treatment and control of parasitic diseases. Leishmania spp., the causative agents of leishmaniasis, have served as...

Cite
Papadopoulou B, Kündig C, Singh A, et al. Drug resistance in Leishmania: similarities and differences to other organisms. Drug Resist Updat. 1998;1(4):266-78doi: 10.1016/s1368-7646(98)80007-1.
Papadopoulou, B., Kündig, C., Singh, A., & Ouellette, M. (1998). Drug resistance in Leishmania: similarities and differences to other organisms. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 1(4), 266-78. https://doi.org/10.1016/s1368-7646(98)80007-1
Papadopoulou, B, et al. "Drug resistance in Leishmania: similarities and differences to other organisms." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 1,4 (1998): 266-78. doi: https://doi.org/10.1016/s1368-7646(98)80007-1
Papadopoulou B, Kündig C, Singh A, Ouellette M. Drug resistance in Leishmania: similarities and differences to other organisms. Drug Resist Updat. 1998;1(4):266-78. doi: 10.1016/s1368-7646(98)80007-1. PMID: 16904409.
Copy Download .nbib Format: NLM
Renal involvement in leishmaniasis: a review of the literature.

NDT plus

Clementi A, Battaglia G, Floris M, Castellino P, Ronco C, Cruz DN.
PMID: 25984144
NDT Plus. 2011 Jun;4(3):147-52. doi: 10.1093/ndtplus/sfr008. Epub 2011 Mar 21.

Leishmaniasis, an infectious disease endemic in tropical, Asian and southern European countries, is caused by obligate intramacrophage protozoa and is transmitted through the bite of infected female sandflies. More than 20 leishmanial species are responsible for four main clinical...

Cite
Clementi A, Battaglia G, Floris M, et al. Renal involvement in leishmaniasis: a review of the literature. NDT Plus. 2011;4(3):147-52doi: 10.1093/ndtplus/sfr008.
Clementi, A., Battaglia, G., Floris, M., Castellino, P., Ronco, C., & Cruz, D. N. (2011). Renal involvement in leishmaniasis: a review of the literature. NDT plus, 4(3), 147-52. https://doi.org/10.1093/ndtplus/sfr008
Clementi, Anna, et al. "Renal involvement in leishmaniasis: a review of the literature." NDT plus vol. 4,3 (2011): 147-52. doi: https://doi.org/10.1093/ndtplus/sfr008
Clementi A, Battaglia G, Floris M, Castellino P, Ronco C, Cruz DN. Renal involvement in leishmaniasis: a review of the literature. NDT Plus. 2011 Jun;4(3):147-52. doi: 10.1093/ndtplus/sfr008. Epub 2011 Mar 21. PMID: 25984144; PMCID: PMC4421603.
Copy Download .nbib Format: NLM
Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients.

World journal of transplantation

Diken AI, Diken OE, Hanedan O, Yılmaz S, Ecevit AN, Erol E, Yalçınkaya A.
PMID: 27011917
World J Transplant. 2016 Mar 24;6(1):193-8. doi: 10.5500/wjt.v6.i1.193.

Despite advances in transplantation techniques and the quality of post-transplantation care, opportunistic infections remain an important cause of complications. Pneumocystis jirovecii (P. jirovecii) is an opportunistic organism, represents an important cause of infections in heart transplantation patients. Almost 2%...

Cite
Diken AI, Diken OE, Hanedan O, et al. Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients. World J Transplant. 2016;6(1):193-8doi: 10.5500/wjt.v6.i1.193.
Diken, A. I., Diken, O. E., Hanedan, O., Yılmaz, S., Ecevit, A. N., Erol, E., & Yalçınkaya, A. (2016). Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients. World journal of transplantation, 6(1), 193-8. https://doi.org/10.5500/wjt.v6.i1.193
Diken, Adem Ilkay, et al. "Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients." World journal of transplantation vol. 6,1 (2016): 193-8. doi: https://doi.org/10.5500/wjt.v6.i1.193
Diken AI, Diken OE, Hanedan O, Yılmaz S, Ecevit AN, Erol E, Yalçınkaya A. Pentamidine in Pneumocystis jirovecii prophylaxis in heart transplant recipients. World J Transplant. 2016 Mar 24;6(1):193-8. doi: 10.5500/wjt.v6.i1.193. PMID: 27011917; PMCID: PMC4801795.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 78 entries